bioAffinity Technologies (BIAF) Current Assets (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Current Assets for 6 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 132.94% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 132.94% YoY), while the FY2025 annual figure was $7.6 million, up 180.7% from the prior year.
• Current Assets eased to $4.3 million in Q1 2026 per BIAF's latest filing, from $7.6 million in the prior quarter.
• Across five years, Current Assets topped out at $14.1 million in Q3 2022 and bottomed at $1.7 million in Q2 2025.
• Historically, Current Assets has averaged $6.1 million across 5 years, with a median of $4.3 million in 2026.
• Annual changes were most pronounced in 2022 — Current Assets surged 731.69% — and 2024, when it sank 69.05%.
• bioAffinity Technologies' Current Assets stood at $12.0 million in 2022, then plunged by 66.79% to $4.0 million in 2023, then slumped by 32.16% to $2.7 million in 2024, then surged by 180.7% to $7.6 million in 2025, then plunged by 42.61% to $4.3 million in 2026.
• Business Quant data shows BIAF's Current Assets at $4.3 million in Q1 2026, $7.6 million in Q4 2025, and $8.6 million in Q3 2025.